Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Single-Dose Study to Evaluate Safety and Efficacy of CS-1103 in Participants With Methamphetamine Use Disorder Not Seeking Treatment Receiving a Single Dose of Methamphetamine

Next Previous
Trial Profile

A Phase 2 Single-Dose Study to Evaluate Safety and Efficacy of CS-1103 in Participants With Methamphetamine Use Disorder Not Seeking Treatment Receiving a Single Dose of Methamphetamine

Status: Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 10 Nov 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CS 1103 (Primary)
  • Indications Drug toxicity; Substance-related disorders
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Clear Scientific

Most Recent Events

  • 30 Sep 2025 Accoridng to Clear Scientific Inc media release, phase 2 trials are expected to begin in Q1 2026.
  • 04 May 2025 Planned End Date changed from 1 Oct 2025 to 6 Feb 2026.
  • 04 May 2025 Planned primary completion date changed from 1 Sep 2025 to 6 Jan 2026.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top